Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12570492 | 0.88 | MEN1 (0.36) | MEN1POLBKMT2A | |
| SCHEMBL12570488 | 0.82 | MEN1 (0.44) | MEN1POLBKMT2A | |
| SCHEMBL9191084 | 0.82 | MEN1 (0.45) | MEN1POLBKMT2AKDM4ECHRM2 | |
| SCHEMBL22953317 | 0.82 | MEN1 (0.50) | MEN1POLBKMT2AKDM4ECHRM2 | |
| SCHEMBL19554733 | 0.82 | MEN1 (0.45) | MEN1POLBKMT2AKDM4ECHRM2 | |
| SCHEMBL4545007 | 0.82 | MEN1 (0.50) | MEN1POLBKMT2AKDM4ECHRM2 | |
| SCHEMBL18323717 | 0.82 | MEN1 (0.50) | MEN1POLBKMT2AKDM4ECHRM2 | |
| SCHEMBL18776435 | 0.78 | PIK3CD (0.33) | MEN1KMT2A | |
| SCHEMBL8530912 | 0.75 | CA2 (0.35) | MEN1POLBKMT2AKDM4E | |
| SCHEMBL28154335 | 0.75 | CA2 (0.35) | MEN1POLBKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960554-B2 | Ambient-temperature molten salts and process for producing the same | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7534509-B2 | Ambient-temperature molten salts and process for producing the same | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070225503-A1 | Ambient-temperature molten salts and process for producing the same | TOYOTA JIDOSHA KABUSHIKI KAISHA | 2007-09-27 | — | — | US | disclosed |
| US-20070203345-A1 | Ambient-temperature molten salts and process for producing the same | TOYOTA JIDOSHA KABUSHIKI KAISHA | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203345-A1 | Ambient-temperature molten salts and process for producing the same | AFF1, AFF2, AFF4 | MEN1 452/4885POLB 3542/4885KMT2A 1973/4885 |
| US-20070225503-A1 | Ambient-temperature molten salts and process for producing the same | AFF1, AFF2, AFF4 | MEN1 452/4885POLB 3542/4885KMT2A 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.